|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Lymphomas in OKT3-treated animals (in contrast to lymphomas in the untreated animals) contained many LMP1-expressing cells.
|
22623780 |
2012 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
LMP-1 30 bp deletion was found in high frequency in both non-neoplastic tonsils (92%) and malignant lymphomas (86%).
|
11920819 |
2002 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
LMP1 effects were also evaluated in the EBV-negative B-lymphoma cell line BL41 and the EBV-positive Burkitt's lymphoma cell line, Daudi (Daudi is deleted for EBNA-2 and does not express LMP).
|
2157887 |
1990 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
LMP1-mediated signaling through the TRAF system has a role in the pathogenesis of the EBV-positive lymphomas that arise in immunosuppressed patients.
|
9580648 |
1998 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A 30-basepair (bp) deletion in the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) gene has been reported in nasopharyngeal carcinoma and EBV-associated malignant lymphomas.
|
9416698 |
1997 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
A 30-bp deletion in the Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) gene has been reported in nasopharyngeal carcinoma and EBV-associated malignant lymphomas.
|
9422536 |
1998 |
|
Lymphoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
A comparative sequence analysis of the fingerprint LMP1 region identified in donor lymphocytes and lymphoma was performed.
|
11502981 |
2001 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Although the latent membrane protein-1 (LMP1) of the Epstein-Barr virus (EBV) is believed to be important for the transformation of germinal centre (GC) B cells, the precise contribution of this viral oncogene to lymphoma development is poorly understood.
|
18566961 |
2008 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of EBV gene transfectants of the B lymphoma lines BJAB and BL41 showed that the virus-encoded latent membrane protein-1 (LMP1), which is one of several EBV antigens expressed in group III but not in group I cells, was uniquely able to up-regulate expression both of the Tap proteins and HLA class I.
|
7774641 |
1995 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Because T cells specific for these antigens are present with low frequency and may be rendered anergic by the tumors that express them, we expanded LMP-cytotoxic T lymphocytes (CTLs) from patients with lymphoma using autologous dendritic cells and EBV-transformed B-lymphoblastoid cell lines transduced with an adenoviral vector expressing either LMP2 alone (n = 17) or both LMP2 and ΔLMP1 (n = 33).
|
24344220 |
2014 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Because the LMP gene has transforming potential, our findings support the concept of a pathoetiologic role for EBV in a proportion of CD30-positive ALC lymphomas.
|
1668608 |
1991 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, BCL-6(-)/LMP-1(+)/BCL-2(+) PCNSL are restricted to HIV-infected hosts and are represented by lymphomas with immunoblastic features.
|
9680371 |
1998 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Deletion variants within the NF-kappa B activation domain of the LMP1 oncogene prevail in acquired immunodeficiency syndrome-related large cell lymphomas and human immunodeficiency virus-negative atypical lymphoproliferations.
|
8562956 |
1996 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Deletion variants within the NF-kappaB activation domain of the LMP1 oncogene in acquired immunodeficiency syndrome-related large cell lymphomas, in prelymphomas and atypical lymphoproliferations.
|
9322886 |
1997 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Differences in EBV association and LMP-1 expression were found between a major group of HIV-associated systemic NHL with blastic cell morphology, including SNCC lymphoma and its variants, and anaplastic cell lymphomas.
|
8394878 |
1993 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
EBV encodes several latent genes, among them latent membrane protein 1 (LMP1) and LMP2A, which are regularly expressed in EBV-positive Hodgkin lymphoma and posttransplantation lymphomas.
|
16076866 |
2005 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
EBV, a human gamma herpesvirus that contributes to the progression of a multitude of lymphomas and carcinomas in immunocompromised or genetically susceptible populations, packages its major oncoprotein, LMP1, into vesicles for secretion.
|
29212935 |
2018 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is crucial for B cell transformation and oncogenesis of other EBV-related malignancies, such as nasopharyngeal carcinoma and T/NK lymphoma.
|
26819314 |
2016 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Epstein-Barr virus latent membrane protein 1 (LMP1) is expressed in multiple human malignancies, including nasopharyngeal carcinoma and Hodgkin and immunosuppression-associated lymphomas.
|
28835489 |
2017 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Further, transient Flag-LMP1 expression in a B-lymphoma cell line transduces signals that upregulate TRAF1 levels but does not alter JAK3 levels or activation state.
|
11739714 |
2002 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the detection of the LMP-1 protein in tumour cells in most SNHLs and some WRNHLs expressing NK and/or T-cell antigens, in view of the LMP-1 transforming potential, suggests that EBV may play a role in the pathogenesis of these lymphomas.
|
8778335 |
1996 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, transfection with LMP1 expression vector into a human B lymphoma cell line, Daudi, led to p40 production with nuclear factor (NF)-kappaB activation.
|
9837745 |
1998 |
|
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gene expression levels of LMP-1, LMP-2A, and LMP-2B and EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C and EBNA-LP were monitored by real-time quantitative-polymerase chain reaction (qRT-PCR) in cells from nine EBV-induced lymphomas and in matched lymphocytes from healthy subjects.
|
26548532 |
2016 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Here, we report that the bioactivity of antcin H, an analog of the JAK2 inhibitor zhankuic acid A (ZAA), inhibits LMP1-induced JAK/STAT related signaling and induces lymphoma cell line apoptosis.
|
30277103 |
2019 |
|
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
However, as many lymphomas only express subdominant EBV antigens that are less immunogenic, novel strategies are needed to manufacture EBV-specific T cell products specific for Latent Membrane Protein 1 (LMP1) and LMP2, which are expressed in lymphomas with type II and III latency.
|
27873282 |
2017 |